Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Eli Lilly Makes Largest Manufacturing Investment In Its History To Boost Production For Antidiabetic And Weight Loss Meds

Published 24/05/2024, 19:03
© Reuters.  Eli Lilly Makes Largest Manufacturing Investment In Its History To Boost Production For Antidiabetic And Weight Loss Meds
LLY
-

Benzinga - by Vandana Singh, Benzinga Editor.

Friday, Eli Lilly And Company (NYSE:LLY) announced it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing its total investment from $3.7 billion to $9 billion.

This expansion will enhance Lilly’s capacity to manufacture active pharmaceutical ingredients (API) for Zepbound (tirzepatide) injection and Mounjaro (tirzepatide) injection.

Related: Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires Manufacturing Facility From Nexus Pharma.

Since 2020, Lilly has committed more than $16 billion to develop new U.S. and European manufacturing sites.

New locations outside Indiana include Research Triangle Park and Concord, North Carolina; Limerick, Ireland; and Alzey, Germany.

Separately, the company has invested an additional $1.2 billion to update existing manufacturing facilities in Indianapolis and recently acquired an injectable manufacturing facility in Pleasant Prairie, Wisconsin, from Nexus Pharmaceuticals.

Together, these manufacturing investments total more than $18 billion.

“Today’s announcement tops the largest manufacturing investment in our company’s history and, we believe, represents the single largest investment in synthetic medicine API manufacturing in U.S. history,” said David Ricks, Lilly’s chair and CEO.

As part of this additional investment in the Lebanon site, located within Indiana’s LEAP Research and Innovation District, Lilly expects to add 200 full-time jobs for highly skilled workers such as engineers, scientists, operating personnel and lab technicians, resulting in an estimated 900 full-time employees when the facility is fully operational.

Additionally, there will be more than 5,000 construction jobs during the site’s development.

In May 2022, Lilly first announced its plans to invest $2.1 billion and create up to 500 new jobs at LEAP.

At the company’s Lebanon groundbreaking in April 2023, Lilly announced an additional $1.6 billion investment and 200 new jobs at the site.

Eli Lilly expects to begin making medicines in Lebanon toward the end of 2026 – with operations scaling up through 2028.

Price Action: LLY shares are up 0.09% at $809.14 at the last check on Friday.

Image by Mohammed_Al_Ali via Shutterstock

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.